Related Experiment Video
Updated: Oct 9, 2026

Harnessing the Bioorthogonal Inverse Electron Demand Diels-Alder Cycloaddition for Pretargeted PET Imaging
Published on: February 3, 2015
In situ construction of a biotinylated [CuII3(POBio)2] complex for tumor-targeted chemodynamic therapy
Yu-Qing Jia1, Di-Yu Yang1, Xiao-Ying Wu1
1Key Laboratory for Chemistry and Molecular Engineering of Medicinal Resources (Ministry of Education of China), Guangxi Key Laboratory of Chemistry and Molecular Engineering of Medicinal Resources, University Engineering Research Center for Chemistry of Characteristic Medicinal Resources (Guangxi), School of Chemistry and Pharmaceutical Sciences, Guangxi Normal University, Guilin 541004, China.
Abstract:
Chemodynamic therapy (CDT) generates cytotoxic hydroxyl radicals (•OH) in tumors via Fenton/Fenton-like reactions using elevated H₂O₂ and acidity. However, its clinical potential is limited by poor tumor selectivity and the difficulty in balancing catalytic metal ion doses with toxicity. In this work, using HPBio (2-Pyridinecarboxaldehyde biotin bis-hydrazide) as the ligand, a biotinylated tri-nuclear copper(II) complex of POBio-Cu3 has been in-situ synthesized. The solution assemble behavior and in-situ oxidation process has been investigated by time-dependent ESI-MS technology. In the atomically precise POBio-Cu3, biotin moiety was acting as a cancer-targeting unit and multi-nuclear Cu(II) core as a GSH depletor for augmented CDT effect. POBio-Cu3 could preferentially accumulate in cancerous Hep-G2 cells, due to the cell discrepancy toward normal WI38 cells. The Cu(II) centers in POBio-Cu3 were available for consuming glutathione (GSH) and amplifying oxidative stress. Furthermore, the results of in vivo experiments showed that POBio-Cu3 could remarkably inhibit tumor growth without significant damage to major organs.

![Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F62334.jpg&w=3840&q=50)